Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05918913 Available - Clinical trials for Relapsed/Refractory Acute Leukemia

Expanded Access Program for Revumenib

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

NCT ID: NCT05738538 Available - Clinical trials for Acute Myeloid Leukemia, With NPM1 Mutations

Expanded Access to Ziftomenib

Start date: n/a
Phase:
Study type: Expanded Access

Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL), with appropriate mutations, or Acute Myeloid Leukemia (AML), with NPM1 mutations. To request access, use Responsible Party contact information provided in this record. Expanded access for ziftomenib is only available in the United States

NCT ID: NCT05593185 Available - Clinical trials for Acute Myeloid Leukemia

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Start date: n/a
Phase:
Study type: Expanded Access

Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.

NCT ID: NCT05219266 Available - Clinical trials for Acute Myeloid Leukemia

Managed Access Programs for PKC412, Midostaurin

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.

NCT ID: NCT03145545 Available - Leukemia Clinical Trials

Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC

Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia Institutional Review Board (IRB) approved protocols that utilize CliniMACs technology for T depletion.

NCT ID: NCT03123029 Available - Multiple Myeloma Clinical Trials

Expanded Access to Venetoclax

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.